McKesson Corporation ($MCK) Stock Forecast: Down 0.8% Today

What is McKesson Corporation?

McKesson Corporation (MCK) is a prominent healthcare services leader known for its operational excellence and long-term financial growth targets. Today, the stock experienced a significant bearish movement in the market.

Why is McKesson Corporation going down?

MCK stock is down 0.8% on May 8, 2026 16:21

• McKesson's bearish movement could be attributed to the company missing revenue estimates in Q1 CY2026 despite showing year-on-year growth, indicating potential concerns about its revenue generation capabilities.
• The announcement of pursuing the separation of its medical-surgical business might have caused uncertainty among investors about the company's future strategic direction, leading to a negative market sentiment.
• Despite exceeding analyst estimates in non-GAAP profit per share and operating income, the mixed performance in revenue could have overshadowed these positive aspects, contributing to the bearish movement in the stock price.
• Investors might be awaiting further insights from the upcoming earnings conference call to gain clarity on McKesson's financial outlook and the impact of its business restructuring initiatives on future profitability.

MCK Price Chart

MCK Technical Analysis

MCK News

McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results, Provides Fiscal 2027 Guidance, and Reaffirms Long-Term Financial Growth Targets

McKesson Corporation announced its fiscal 2026 fourth-quarter and full-year financial results, which are available on its Investor Relations website. The company will host a live webcast of an earnings conference call on May 7, 2026, at 4:30 PM ET to discuss these results. McKesson, a healthcare services leader, also reaffirms its long-term financial growth targets and provides fiscal 2027 guidance.

https://www.biospace.com/press-releases/mckesson-reports-fiscal-2026-fourth-quarter-and-full-year-results-provides-fiscal-2027-guidance-and-reaffirms-long-term-financial-growth-targets

McKesson anticipates fiscal 2027 adjusted EPS of $43.80-$44.60 while advancing medical-surgical separation

McKesson announced its fiscal 2027 outlook, projecting adjusted earnings per share between $43.80 and $44.60. The company is actively pursuing the separation of its medical-surgical business, indicating a strategic shift in its operational focus. This financial guidance provides insight into McKesson's future performance and business restructuring.

https://www.msn.com/en-us/money/companies/mckesson-anticipates-fiscal-2027-adjusted-eps-of-43-80-44-60-while-advancing-medical-surgical-separation/ar-AA22DJF6?ocid=finance-verthp-feeds

McKesson Corporation 2026 Q4 - Results - Earnings Call Presentation (NYSE:MCK) 2026-05-07

McKesson Corporation published a slide deck in anticipation of their 2026 Q4 earnings call. The article is a notice of this publication, provided by Seeking Alpha's transcripts team. This team is responsible for publishing numerous quarterly earnings call transcripts and updates readers on new developments.

https://seekingalpha.com/article/4900776-mckesson-corporation-2026-q4-results-earnings-call-presentation

McKesson (NYSE:MCK) Misses Q1 CY2026 Revenue Estimates

McKesson (NYSE:MCK) missed market revenue estimates in Q1 CY2026, with sales of $96.3 billion despite a 6% year-on-year growth. However, the company's non-GAAP profit per share of $11.69 exceeded analyst estimates by 1.1%. The results show a mixed performance, with revenue falling short but adjusted EPS and operating income surpassing expectations.

https://www.theglobeandmail.com/investing/markets/stocks/MCK/pressreleases/1786660/mckesson-nysemck-misses-q1-cy2026-revenue-estimates/

McKesson (NYSE:MCK) Misses Q1 CY2026 Revenue Estimates

McKesson (NYSE:MCK) reported mixed Q1 CY2026 results, with revenue falling short of analyst estimates at $96.3 billion despite a 6% year-on-year increase. However, the company beat on non-GAAP profit, reporting $11.69 per share, slightly above consensus. The article highlights the company's historical revenue growth, stable adjusted operating margin, and EPS growth largely driven by share repurchases.

https://stockstory.org/us/stocks/nyse/mck/news/earnings/mckesson-nysemck-misses-q1-cy2026-revenue-estimates

Trending Today

McKesson Corporation Price History

05.01.2026 - MCK Stock was up 16.6%

• McKesson experienced a strong bullish movement today due to robust fiscal third-quarter results, particularly in key segments like oncology and pharmaceutical distribution.
• The planned IPO of its medical surgical business by the second half of 2027 demonstrates a strategic shift towards a more focused approach.
• Positive sentiment surrounding McKesson's financial performance and surpassing analyst expectations have led to an all-time high stock price, boosting investor confidence.
• McKesson's solid operational strategies, strong financial results, and growth potential in the healthcare sector have made it an attractive investment option, contributing to the bullish market movement.

05.01.2026 - MCK Stock was up 13.6%

• Strong fiscal third-quarter results were reported by McKesson, with a focus on oncology, biopharma services, and pharmaceutical distribution, leading to a bullish market movement.
• The company's strategic shift towards its core drug distribution and services, as well as the potential IPO of its medical surgical business, has garnered positive investor sentiment and contributed to the stock's surge.
• Despite a Zacks Rank of #3 (Hold) and cautious outlook, the overall market response to McKesson's robust operational strategies and exceeding analyst expectations in Q3 fiscal 2026 results has been overwhelmingly positive, driving the stock to new heights.

05.01.2026 - MCK Stock was up 13.6%

• MCK witnessed a strong uptrend in trading today.
• This positive movement could be linked to the company's Q3 2026 results, where although revenue slightly missed expectations, the adjusted EPS exceeded forecasts. This robust performance and the raised annual profit guidance likely bolstered investor confidence.
• The favorable atmosphere in the healthcare domain, exemplified by Cardinal Health (CAH) surpassing estimates and revising its profit outlook due to heightened demand for specialized medications, may have further influenced MCK's upward trajectory.
• Investors seem positive about McKesson's strategic positioning in healthcare, particularly its emphasis on specialty pharmaceuticals and potential growth prospects within the market.

08.04.2026 - MCK Stock was down 0.8%

• McKesson's bearish movement could be attributed to the company missing revenue estimates in Q1 CY2026 despite showing year-on-year growth, indicating potential concerns about its revenue generation capabilities.
• The announcement of pursuing the separation of its medical-surgical business might have caused uncertainty among investors about the company's future strategic direction, leading to a negative market sentiment.
• Despite exceeding analyst estimates in non-GAAP profit per share and operating income, the mixed performance in revenue could have overshadowed these positive aspects, contributing to the bearish movement in the stock price.
• Investors might be awaiting further insights from the upcoming earnings conference call to gain clarity on McKesson's financial outlook and the impact of its business restructuring initiatives on future profitability.

08.00.2026 - MCK Stock was down 2.2%

• The bearish movement in MCK's stock today could be attributed to the insider selling activity by Thomas Rodgers, the Chief Strategy & Business Development Officer. This could have raised concerns among investors about the company's future prospects.
• The fresh analyst commentary on McKesson's valuation, while highlighting its strong performance and earnings potential, may not have been enough to offset the impact of the insider selling news.
• The overall market sentiment towards healthcare supply chain companies like McKesson might have been affected by the potential risks mentioned, such as drug pricing pressures and vertical integration by manufacturers, leading to a bearish trend in the stock price.
• Despite the positive outlook on injectable GLP-1 drugs driving demand for related companies like West Pharmaceutical Services, the focus on McKesson's insider selling and valuation concerns could have overshadowed any potential industry growth prospects, contributing to the bearish movement in the stock.

20.02.2026 - MCK Stock was down 5.4%

• The strong bearish movement in McKesson's stock today could be attributed to profit-taking by insiders despite the positive quarterly earnings and analyst recommendations.
• The acquisition of shares by CIBC Bancorp USA Inc. might have initially boosted investor confidence, but the subsequent insider selling could have raised concerns among traders.
• The price target adjustment to $1,010 from $974, while maintaining an Outperform rating, could have created uncertainty among investors, leading to a sell-off.
• Overall, the mixed signals from insider selling, institutional acquisitions, and price target adjustments might have contributed to the bearish market movement in McKesson's stock today.

05.02.2026 - MCK Stock was down 5.1%

• The announcement of a forthcoming CFO transition elicited uncertainty among investors, potentially prompting a sell-off of McKesson stock.
• EVP Michele Lau's insider selling of shares, despite the company's robust Q3 fiscal 2026 performance, could have indicated to investors a profit-taking behavior among insiders.
• Negative market sentiment towards McKesson may have been fueled by broader industry developments, including upcoming conferences highlighting risks and debt concerns in related companies like Henry Schein.
• The stock's decline in midday trading, coupled with a notable decrease in executive ownership, likely influenced the bearish movement as investors reassessed their positions in McKesson.

05.02.2026 - MCK Stock was down 5.9%

• The decline in McKesson's stock price could be linked to the upcoming CFO transition, causing investor uncertainty about the company's future strategic and financial direction.
• The sale of $2.69 million in stock by McKesson's EVP and Chief Legal Officer may have also influenced the negative investor sentiment, highlighting insider selling activities.
• Despite outperforming analyst projections in Q3 fiscal 2026, concerns regarding the CFO transition and insider selling could have overshadowed this positive achievement, resulting in the decline in the stock market.
• Investors are likely keeping a close eye on McKesson's upcoming capital allocation strategies, including the potential Med-Surg spin-off and specialty acquisitions, to evaluate their potential impact on the company's financial prospects and stock performance.

12.01.2026 - MCK Stock was down 4.2%

• The stock of McKesson (MCK) experienced a bearish movement despite positive developments and strong third-quarter results.
• The refocusing on North American operations and the spin-off of the medical-surgical segment might have initially raised concerns among investors about the company's future growth prospects.
• Interoperability challenges in the healthcare sector could have contributed to market uncertainty, potentially impacting McKesson's stock performance.
• Despite positive outlook from analysts and the company's strategic moves, investors may be cautious about the potential risks associated with the shift in focus and the broader industry challenges.

06.00.2026 - MCK Stock was up 1.8%

• An institutional investor, Robeco Institutional Asset Management B.V., notably increased its holdings in McKesson Corporation, indicating strong confidence in the company's future.
• McKesson's Q3 earnings surpassed expectations, with earnings per share exceeding forecasts and a 10.2% revenue growth from the previous year, potentially boosting investor confidence.
• The company's emphasis on specialty and automation services, coupled with strategic expansions like venturing into the biopharma and provider ecosystem, played a key role in driving its positive earnings trajectory.
• Positive sentiments from analysts, institutional investors, and the company's financial performance likely contributed to the recent bullish movement in McKesson's stock.

06.04.2026 - MCK Stock was down 6.0%

• The bearish movement in McKesson's stock today could be attributed to investors' cautious approach ahead of the upcoming earnings report.
• Analysts' suggestions of a possible slowdown in year-on-year revenue growth might have contributed to the negative sentiment surrounding the stock.
• Trading below the average analyst price target, McKesson's shares have underperformed in the past month, potentially intensifying the bearish movement.
• Despite the positive sentiment in the broader healthcare providers & services segment, McKesson's financial outlook and recent stock performance appear to have diminished investor confidence, prompting the bearish market movement.

06.04.2026 - MCK Stock was down 6.7%

• McKesson agreed to a $1.25 billion deal with Apollo Global Management for a minority stake in its Medical-Surgical Solutions (MMS) business, valuing the unit at around $13 billion. This move towards separation and a potential IPO raised concerns among investors about the company's future and earnings impact.
• Anticipation surrounds McKesson's upcoming earnings report, with projections of an 11.9% year-on-year revenue increase. Despite positive healthcare sector sentiment, the stock's recent decline might reflect investor caution ahead of the financial results.
• Emerging news about Rigel Pharmaceuticals and Bristol Myers Squibb harnessing AI in drug manufacturing has diverted investor focus away from McKesson, influencing its stock price negatively.
• The discontinuation of a global strategic partnership with Lilly and changes to credit agreements have added uncertainty to McKesson's outlook. Investors closely monitoring the company's strategic decisions and developments have contributed to a bearish sentiment towards the stock.